• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Imitrex (sumatriptan) tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – August 2010

Summary View

PRECAUTIONS

Nursing Mothers
  • Sumatriptan is excreted in human breast milk following subcutaneous administration. Infant exposure to sumatriptan can be minimized by avoiding breastfeeding for 12 hours after treatment with Imitrex tablets.
 WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT INFORMATION
  • Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome: Cases of life-threatening serotonin syndrome have been reported during combined use of SSRIs or SNRIs and triptans
  • Patients should be cautioned about the risk of serotonin syndrome with the concomitant use of triptans and SSRIs or SNRIs.
  • Some people may have a reaction called serotonin syndrome when they use certain types of antidepressants, SSRIs or SNRIs, while takingtriptan. Symptoms may include confusion, hallucinations, fast heart beat, feeling faint, fever, sweating, muscle spasm, difficulty walking, and/or diarrhea. Call your doctor immediately if you have any of these symptoms after taking triptan.